spacer
home > epc > summer 2019 > preparations for the new eu portal
PUBLICATIONS
European Pharmaceutical Contractor

Preparations for the New EU Portal





The EMA is developing a new clinical trial information system (CTIS) that will provide a single portal for submitting and managing clinical trial application (CTA) dossiers, authorisations, and transparency. While this new system is not expected to be live until late in 2020, organisations should be preparing now for the significant process and systems changes that the CTIS will require.

Before a clinical trial can be conducted in the EU, a dossier must be submitted for approval. Once approved, a trial requires the submission of protocol amendments, status updates, and results information after the trial has completed. For trials with paediatric participants, results are required within six months of the end of trial, while trials in adults require results within 12 months.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


As TrialScope’s Chief Strategy Officer, Thomas Wicks is responsible for the strategy of clinical trial disclosure and transparency solutions. He has more than 20 years of experience with performance and content management solutions, specialising in applications for life sciences such as clinical trial disclosure, structured product labelling, and submissions management. He has been focused on trial transparency since 2007.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge CPhI & P-MEC China a direct result of surging manufacturing

Shanghai, 22 July, 2019:CPhI and P-MEC China – organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, and Shanghai Sinoexpo Informa Markets – saw record numbers of attendees as the pharma market in China continues to grow. The three-day Shanghai event featured 3,200+ exhibiting companies, spanning the entire pharma supply chain, and provides a strong indication of the market’s overall growth patterns and future development.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement